Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.

@article{Zhao2006PreclinicalEO,
  title={Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.},
  author={Yan Zhao and Huw D. Thomas and Michael A. Batey and Ian G. Cowell and Caroline J. Richardson and Roger John Griffin and Alan Hilary Calvert and David Richard Newell and Graeme C M Smith and Nicola J. Curtin},
  journal={Cancer research},
  year={2006},
  volume={66 10},
  pages={
          5354-62
        }
}
DNA double-strand breaks (DSB) are the most cytotoxic lesions induced by ionizing radiation and topoisomerase II poisons, such as etoposide and doxorubicin. A major pathway for the repair of DSB is nonhomologous end joining, which requires DNA-dependent protein kinase (DNA-PK) activity. We investigated the therapeutic use of a potent, specific DNA-PK inhibitor (NU7441) in models of human cancer. We measured chemosensitization by NU7441 of topoisomerase II poisons and radiosensitization in cells… Expand
DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.
TLDR
NU7441 inhibited the growth of NSCLC cells and enhanced the chemosensitization to topoisomerase inhibitors by blocking DNA repair, and may be a promising treatment forNSCLC. Expand
Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K
TLDR
The proof-of-principle in vitro and in vivo chemosensitization with KU-0060648 justifies further evaluation of dual DNA-PK and PI-3K inhibitors. Expand
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
TLDR
KU59403 provides the first proof-of-principle preclinical data to support the future clinical development of ATM inhibitors, being the first compound to show good tissue distribution and significant chemosensitization in in vivo models of human cancer, without major toxicity. Expand
DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells
TLDR
It is shown that PRKDC levels were enhanced in neuroblastoma patients and correlated with a more advanced tumor stage and poor prognosis, making DNA-PKcs an interesting target for radiosensitization of Neuroblastoma tumors. Expand
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
TLDR
Data confirm NU7441 not only as a potent chemo- and radio-sensitiser clinical candidate but also as a powerful tool to study the biology of DNA-PK. Expand
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
TLDR
The authors show that the DNA-PK inhibitor AZD7648 enhances the activity of radiotherapy, chemotherapy and the PARP inhibitor olaparib in multiple mouse tumour models, enabling sustained tumour regression and providing a clear rationale for its clinical investigation. Expand
DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin
TLDR
The data indicate that DNA-PK might be an effective target for chemo- and radio-potentiation in breast cancer and suggest that further development of DNA- PK inhibitors for clinical use is warranted. Expand
Chemical Therapeutics Preclinical Evaluation of a Novel ATM Inhibitor , KU 59403 , In Vitro and In Vivo in p 53 Functional and Dysfunctional Models of Human Cancer
Ataxia telangiectasia mutated (ATM) kinase signals DNA double-strand breaks (DSB) to cell-cycle arrest via p53 and DNA repair. ATM-defective cells are sensitive to DSB-inducing agents, making ATM anExpand
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
TLDR
It may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235, which resulted in striking tumor radiosensitization, which extended the survival of brain tumor–bearing mice. Expand
Radiosensitizing activity of novel small molecule BRCA1 and DNA-PK inhibitors in lung and colon carcinoma
Abstract The DNA dependant protein kinase (DNA-PK) enzyme plays a major part in the repair of double stranded breaks induced by radiation and hence in the radio-resistance of tumour cells. InhibitorsExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
TLDR
The use of a selective small-molecule inhibitor of DNA repair to potentiate topoisomerase II (topo II) poisons is reported for the first time, identifying DNA-dependent protein kinase (DNA-PK) as a potential target for leukemia therapy. Expand
Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
TLDR
There was a correlation between the ability of the inhibitors to prevent IR-induced DNA DSB repair and their ability to potentiate cytotoxicity and the DNA-PK and PARP-1 inhibitors show potential as tools for anticancer therapeutic intervention. Expand
DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer.
TLDR
These studies validate DNA-PK as a cancer drug target and suggest a new approach for enhancing the effects of existing cancer therapies, which synergistically enhances radiation-induced tumor control in a mouse-human xenograft assay. Expand
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
TLDR
AG14361 is, to the authors' knowledge, the first high-potency PARP-1 inhibitor with the specificity and in vivo activity to enhance chemotherapy and radiation therapy of human cancer. Expand
Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.
TLDR
Inhibition of cellular DNA-PK activity occurred at the same concentrations of wortmannin that caused radiosensitization, and this correlation was found in a range of tumor cell lines, suggesting a new class of radiosensitizers that inhibit the repair of DNA damage. Expand
DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
TLDR
The results suggest that the xrs repair pathway is required for efficient removal of potentially cytotoxic DSBs that arise in cells treated with topoisomerase II inhibitors. Expand
Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin.
TLDR
Investigation of the effects of the protein kinase inhibitor wortmannin on the cytotoxic mechanisms of etoposide and ionising radiation in the Chinese hamster ovary K1 cell line suggests that WM inhibits in intact cells both DNA-PK and either or both the AT-related gene products ATM and ATR. Expand
Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair
TLDR
Combined inhibition of PARP-1 and DNA-PK are pointed to as a powerful strategy for tumor radiosensitization and DSB levels are shown to be caused by a decrease in DSB repair, and not by the formation of additional DSBs. Expand
DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer.
TLDR
It is suggested, that different DSB repair rates among tumor cell subpopulations of individual SCLC tumors may be a major determinant for the variation in clinical treatment effect observed in human SclC tumors of identical histological subtype. Expand
Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors.
TLDR
A correlation between an inability to rejoin double strand breaks and sensitivity to topoisomerase II targeting antitumor drugs is demonstrated. Expand
...
1
2
3
4
5
...